Advertisement

Topics

Mallinckrodt’s Phase IV registry for PPHN medicine starts enrolment

19:00 EDT 1 Aug 2017 | Net Resources International

Mallinckrodt Pharmaceuticals has started patient enrolment in a Phase IV registry (PaTTerN) to evaluate INOMAX (nitric oxide) gas inhalation to treat persistent pulmonary hypertension of the newborn (PPHN).

Original Article: Mallinckrodt’s Phase IV registry for PPHN medicine starts enrolment

NEXT ARTICLE

More From BioPortfolio on "Mallinckrodt’s Phase IV registry for PPHN medicine starts enrolment"

Quick Search
Advertisement
 

Relevant Topic

Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of affected individuals. Symptoms can range from mild breathles...